174 related articles for article (PubMed ID: 37019377)
1. Modeling the interaction between donor-derived regulatory T cells and effector T cells early after allogeneic hematopoietic stem cell transplantation.
Nishiyama N; Ruoff P; Jimenez JC; Miwakeichi F; Nishiyama Y; Yata T
Biosystems; 2023 May; 227-228():104889. PubMed ID: 37019377
[TBL] [Abstract][Full Text] [Related]
2. PD-1 and CTLA-4 up regulation on donor T cells is insufficient to prevent GvHD in allo-HSCT recipients.
Hossain MS; Kunter GM; El-Najjar VF; Jaye DL; Al-Kadhimi Z; Taofeek OK; Li JM; Waller EK
PLoS One; 2017; 12(9):e0184254. PubMed ID: 28953925
[TBL] [Abstract][Full Text] [Related]
3. Improved NK Cell Recovery Following Use of PTCy or Treg Expanded Donors in Experimental MHC-Matched Allogeneic HSCT.
Wolf D; Barreras H; Copsel SN; Komanduri KV; Levy RB
Transplant Cell Ther; 2022 Jun; 28(6):303.e1-303.e7. PubMed ID: 35302008
[TBL] [Abstract][Full Text] [Related]
4. Responses of regulatory and effector T-cells to low-dose interleukin-2 differ depending on the immune environment after allogeneic stem cell transplantation.
Meguri Y; Asano T; Yoshioka T; Iwamoto M; Ikegawa S; Sugiura H; Kishi Y; Nakamura M; Sando Y; Kondo T; Sumii Y; Maeda Y; Matsuoka KI
Front Immunol; 2022; 13():891925. PubMed ID: 35983059
[TBL] [Abstract][Full Text] [Related]
5. TNFR2 blockade of regulatory T cells unleashes an antitumor immune response after hematopoietic stem-cell transplantation.
Moatti A; Debesset A; Pilon C; Beldi-Ferchiou A; Leclerc M; Redjoul R; Charlotte F; To NH; Bak A; Belkacemi Y; Salomon BL; Issa F; Michonneau D; Maury S; Cohen JL; Thiolat A
J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35387779
[TBL] [Abstract][Full Text] [Related]
6. HIF-1α inhibitor echinomycin reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect.
Yao Y; Wang L; Zhou J; Zhang X
J Transl Med; 2017 Feb; 15(1):28. PubMed ID: 28183349
[TBL] [Abstract][Full Text] [Related]
7. Treg-targeted IL-2/anti-IL-2 complex controls graft-
Thiolat A; Pilon C; Caudana P; Moatti A; To NH; Sedlik C; Leclerc M; Maury S; Piaggio E; Cohen JL
Haematologica; 2024 Jan; 109(1):129-142. PubMed ID: 37706355
[TBL] [Abstract][Full Text] [Related]
8. Gut microbiota intervention by pre and probiotics can induce regulatory T cells and reduce the risk of severe acute GVHD following allogeneic hematopoietic stem cell transplantation.
Yazdandoust E; Hajifathali A; Roshandel E; Zarif MN; Pourfathollah AA; Parkhideh S; Mehdizadeh M; Amini-Kafiabad S
Transpl Immunol; 2023 Jun; 78():101836. PubMed ID: 37037266
[TBL] [Abstract][Full Text] [Related]
9. [Effect of donor CD4+CD25+ regulatory T cells on hematopoietic and immune reconstitution, GVHD and disease-free survival after allogeneic hematopoietic stem cell transplantation].
Yang K; Fan ZP; Liu QF; Zhang Y
Nan Fang Yi Ke Da Xue Xue Bao; 2008 Apr; 28(4):537-41. PubMed ID: 18495584
[TBL] [Abstract][Full Text] [Related]
10. CTLA-4 blockade following relapse of malignancy after allogeneic stem cell transplantation is associated with T cell activation but not with increased levels of T regulatory cells.
Zhou J; Bashey A; Zhong R; Corringham S; Messer K; Pu M; Ma W; Chut T; Soiffer R; Mitrovich RC; Lowy I; Ball ED
Biol Blood Marrow Transplant; 2011 May; 17(5):682-92. PubMed ID: 20713164
[TBL] [Abstract][Full Text] [Related]
11. Graft Engineering and Adoptive Immunotherapy: New Approaches to Promote Immune Tolerance After Hematopoietic Stem Cell Transplantation.
Bertaina A; Roncarolo MG
Front Immunol; 2019; 10():1342. PubMed ID: 31354695
[TBL] [Abstract][Full Text] [Related]
12. [Immune tolerance induced by cytokines in allogeneic hematopoietic stem cell transplantation].
Chang YJ; Huang XJ
Beijing Da Xue Xue Bao Yi Xue Ban; 2009 Apr; 41(2):208-11. PubMed ID: 19377632
[TBL] [Abstract][Full Text] [Related]
13. Mocravimod, a Selective Sphingosine-1-Phosphate Receptor Modulator, in Allogeneic Hematopoietic Stem Cell Transplantation for Malignancy.
Dertschnig S; Gergely P; Finke J; Schanz U; Holler E; Holtick U; Socié G; Medinger M; Passweg J; Teshima T; Stylianou C; Oehen S; Heim D; Bucher C
Transplant Cell Ther; 2023 Jan; 29(1):41.e1-41.e9. PubMed ID: 36343893
[TBL] [Abstract][Full Text] [Related]
14. Emerging translational strategies and challenges for enhancing regulatory T cell therapy for graft-versus-host disease.
Hippen KL; Hefazi M; Larson JH; Blazar BR
Front Immunol; 2022; 13():926550. PubMed ID: 35967386
[TBL] [Abstract][Full Text] [Related]
15. The impact of regulatory T cells on the graft-versus-leukemia effect.
Pacini CP; Soares MVD; Lacerda JF
Front Immunol; 2024; 15():1339318. PubMed ID: 38711496
[TBL] [Abstract][Full Text] [Related]
16. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
17. Control of GVHD by regulatory T cells depends on TNF produced by T cells and TNFR2 expressed by regulatory T cells.
Leclerc M; Naserian S; Pilon C; Thiolat A; Martin GH; Pouchy C; Dominique C; Belkacemi Y; Charlotte F; Maury S; Salomon BL; Cohen JL
Blood; 2016 Sep; 128(12):1651-9. PubMed ID: 27506541
[TBL] [Abstract][Full Text] [Related]
18. Marked in Vivo Donor Regulatory T Cell Expansion via Interleukin-2 and TL1A-Ig Stimulation Ameliorates Graft-versus-Host Disease but Preserves Graft-versus-Leukemia in Recipients after Hematopoietic Stem Cell Transplantation.
Wolf D; Barreras H; Bader CS; Copsel S; Lightbourn CO; Pfeiffer BJ; Altman NH; Podack ER; Komanduri KV; Levy RB
Biol Blood Marrow Transplant; 2017 May; 23(5):757-766. PubMed ID: 28219835
[TBL] [Abstract][Full Text] [Related]
19. Ultra low-dose IL-2 for GVHD prophylaxis after allogeneic hematopoietic stem cell transplantation mediates expansion of regulatory T cells without diminishing antiviral and antileukemic activity.
Kennedy-Nasser AA; Ku S; Castillo-Caro P; Hazrat Y; Wu MF; Liu H; Melenhorst J; Barrett AJ; Ito S; Foster A; Savoldo B; Yvon E; Carrum G; Ramos CA; Krance RA; Leung K; Heslop HE; Brenner MK; Bollard CM
Clin Cancer Res; 2014 Apr; 20(8):2215-25. PubMed ID: 24573552
[TBL] [Abstract][Full Text] [Related]
20. Bone marrow-derived mesenchymal stem cells decrease acute graft-versus-host disease after allogeneic hematopoietic stem cells transplantation.
Tian Y; Deng YB; Huang YJ; Wang Y
Immunol Invest; 2008; 37(1):29-42. PubMed ID: 18214798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]